CONNECT WITH US
HealthTech

HealthTech

CVRx names John Landry as CFO

MedTech Dive logo

Published on

Add as a preferred source on Google
CVRx names John Landry as CFO

Landry joins in the aftermath of an investor’s call for the sale of the heart failure device company.

CVRx said Monday that John Landry will join the company next month to fill the CFO post being vacated by Jared Oasheim.

The company, which sells the Barostim heart failure device, received notice in June that Oasheim plans to step down. Landry is leaving Nyxoah, which sells a sleep apnea device, to fill the vacancy. Landry previously served as CFO of Vapotherm, a respiratory technology company.

Landry is “exactly the kind of finance leader we need for this next chapter,” CVRx CEO Kevin Hykes said in a statement. Hykes, who joined CVRx as CEO in 2024, highlighted Landry’s experience of “building and financing high-growth medical device companies.”

Landry will join CVRx on Oct. 12 and take over as CFO when the company files its 10-Q financial filing for the quarter ending Sept. 30. Consistent with the previously disclosed transition, Oasheim will remain at CVRx for a period to smooth the leadership change.

CVRx is under pressure to improve commercial performance. Last month, the company cut its full-year revenue forecast. The cut reflected rapid hiring that “strained our onboarding and training processes and the ability of our area sales directors to spend the time necessary to accelerate these new team members up the productivity curve,” Hykes said on an earnings call.

” The investor, Pointillist Family Office, cited “three guidance resets in three years and a near-term outlook that implies little growth” as evidence of the need for change.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.